A Phase 3 interventional study of IDP-121 Lotion and IDP-121 Vehicle Lotion in Acne, sponsored by Bausch Health Americas, Inc.. Completed at 39 sites in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 3rd largest by enrollment of the 35 interventional ones that give a count, is one of 8 that started in 2015, is one of 13 in phase 3, and was the 23rd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
By country, each count listing its studies:
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 820 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 247 across the 35 interventional studies, 200 across the 1 observational. Of the 31 that completed or were terminated, 19 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score [EGSS] of 3 [moderate] or 4 [severe]).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IDP-121 lotion (tretinoin 0.05 percent \[%\]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
Drug: IDP-121 Lotion
IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
Drug: IDP-121 Vehicle Lotion
IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12
Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.
Time frame: Baseline (Day 0), Week 12
Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12
Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.
Time frame: Baseline, Week 12
Percentage of Participants With Treatment Success at Week 12
Treatment success was defined as at least a 2-grade reduction from Baseline in EGSS score and an EGSS score equating to "Clear" or "Almost Clear". EGSS was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.
Time frame: Baseline, Week 12
Percent Change From Baseline in Noninflammatory Lesion Count to Week 12
Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.
Time frame: Baseline, Week 12
Percent Change From Baseline in Inflammatory Lesion Count to Week 12
Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.
Time frame: Baseline, Week 12
| Milestone | IDP-121 Lotion | IDP-121 Vehicle Lotion |
|---|---|---|
| Started | 406 | 414 |
| Intent-to-treat (itt) population | 406 | 414 |
| Safety population | 378 | 385 |
| Completed | 338 | 337 |
| Not completed | 68 | 77 |
| Withdrew: Withdrawal by subject | 16 | 25 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Pregnancy | 2 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Noncompliance with study drug | 1 | 1 |
| Withdrew: Lost to follow-up | 36 | 40 |
| Withdrew: Withdrawal by parent or guardian | 6 | 8 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Worsening condition | 2 | 0 |
| Withdrew: Withdrew due to burning,itching,stinging | 1 | 0 |
Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.
| lesion count | IDP-121 Lotion | IDP-121 Vehicle Lotion |
|---|---|---|
| Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 | -17.8 ± 15.18 | -10.6 ± 16.07 |
Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.
| lesion count | IDP-121 Lotion | IDP-121 Vehicle Lotion |
|---|---|---|
| Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12 | -13.1 ± 10.50 | -10.2 ± 10.87 |
Treatment success was defined as at least a 2-grade reduction from Baseline in EGSS score and an EGSS score equating to "Clear" or "Almost Clear". EGSS was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.
| percentage of participants | IDP-121 Lotion | IDP-121 Vehicle Lotion |
|---|---|---|
| Percentage of Participants With Treatment Success at Week 12 | 16.5 | 6.9 |
Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.
| percent change | IDP-121 Lotion | IDP-121 Vehicle Lotion |
|---|---|---|
| Percent Change From Baseline in Noninflammatory Lesion Count to Week 12 | -47.5 ± 41.92 | -27.3 ± 43.96 |
Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.
| percent change | IDP-121 Lotion | IDP-121 Vehicle Lotion |
|---|---|---|
| Percent Change From Baseline in Inflammatory Lesion Count to Week 12 | -50.9 ± 40.72 | -40.4 ± 42.29 |
Collected over Baseline (Day 0) up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDP-121 Lotion | 0/378 (0%) | 5/378 (1.3%) | 0/378 (0%) |
| IDP-121 Vehicle Lotion | 0/385 (0%) | 2/385 (0.5%) | 0/385 (0%) |
| Event | IDP-121 Lotion | IDP-121 Vehicle Lotion |
|---|---|---|
| PregnancyPregnancy, puerperium and perinatal conditions | 2/229 | 1/247 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/229 | 1/247 |
| AppendicitisInfections and infestations | 1/378 | 0/385 |
| Calculus uretericRenal and urinary disorders | 1/378 | 0/385 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/378 | 0/385 |
| Alcoholic pancreatitisGastrointestinal disorders | 0/378 | 1/385 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/378 | 1/385 |
ITT analysis set included all randomized participants who received study drug.
| Age, Continuous(years) | IDP-121 Lotion | IDP-121 Vehicle Lotion | Total |
|---|---|---|---|
| Mean | 20.3 ± 7.15 | 20.5 ± 7.26 | 20.4 ± 7.20 |
| Sex: Female, Male(Participants) | IDP-121 Lotion | IDP-121 Vehicle Lotion | Total |
|---|---|---|---|
| Female | 229 | 247 | 476 |
| Male | 177 | 167 | 344 |
| Ethnicity (NIH/OMB)(Participants) | IDP-121 Lotion | IDP-121 Vehicle Lotion | Total |
|---|---|---|---|
| Hispanic or Latino | 146 | 168 | 314 |
| Not Hispanic or Latino | 260 | 246 | 506 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | IDP-121 Lotion | IDP-121 Vehicle Lotion | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 1 | 5 |
| Asian | 20 | 20 | 40 |
| Native Hawaiian or Other Pacific Islander | 3 | 5 | 8 |
| Black or African American | 75 | 72 | 147 |
| White | 296 | 308 | 604 |
| More than one race | 8 | 8 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Evaluator's Global Severity Score (EGSS)(Participants) | IDP-121 Lotion | IDP-121 Vehicle Lotion | Total |
|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 |
| 1 - Almost Clear | 0 | 0 | 0 |
| 2 - Mild | 0 | 0 | 0 |
| 3 - Moderate | 368 | 366 | 734 |
| 4 - Severe | 37 | 48 | 85 |
| Noninflammatory Lesion Count(lesion count) | IDP-121 Lotion | IDP-121 Vehicle Lotion | Total |
|---|---|---|---|
| Mean | 38.0 ± 15.67 | 39.2 ± 16.70 | 38.6 ± 16.20 |
| Inflammatory Lesion Count(lesion count) | IDP-121 Lotion | IDP-121 Vehicle Lotion | Total |
|---|---|---|---|
| Mean | 26.1 ± 5.56 | 26.4 ± 5.63 | 26.3 ± 5.60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2015 to primary completion in Feb 2017, 15 months.
Results were first posted in Jan 2020, 2 years 10 months after primary completion. A results delay was requested in Jan 2018.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 15 months is above that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IDP-121
Bausch Health Americas, Inc. →